Lessons learned from Systolic Blood Pressure Intervention Trial. 2017

Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
aDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine bDepartment of Medicine, Tulane University School of Medicine cResearch Division, Ochsner Health System, New Orleans, Louisiana, USA.

OBJECTIVE The optimal blood pressure (BP) goal during treatment of hypertension has been controversial. In this report, recent articles that elaborate on this issue are reviewed. RESULTS Results from the Systolic Blood Pressure Intervention Trial (SPRINT) have suggested substantial benefits from more intensive BP lowering than is recommended in current US BP management guidelines. CONCLUSIONS Increasing evidence suggests that intensive BP lowering provides a cost-effective means to improve health in many adults with high BP. SPRINT provides the most convincing confirmation, but experience in other trials, alone and in pooled analyses augments and broadens the evidence base to patient groups who were not included in SPRINT. Implementation trials to document feasibility and effectiveness of SPRINT-like interventions in routine practice, including in resource-constrained settings, are warranted.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D013599 Systole Period of contraction of the HEART, especially of the HEART VENTRICLES. Systolic Time Interval,Interval, Systolic Time,Intervals, Systolic Time,Systoles,Systolic Time Intervals,Time Interval, Systolic,Time Intervals, Systolic

Related Publications

Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
August 2019, Cardiology clinics,
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
May 2018, Hypertension (Dallas, Tex. : 1979),
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
August 2016, Hypertension (Dallas, Tex. : 1979),
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
August 2019, Journal of hypertension,
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
October 2016, The American journal of medicine,
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
November 2009, Patient preference and adherence,
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
January 2015, Current pharmaceutical design,
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
November 2020, European heart journal. Cardiovascular pharmacotherapy,
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
June 2016, Clinical trials (London, England),
Paul K Whelton, and Jing Chen, and Marie Krousel-Wood
January 2022, Journal of human hypertension,
Copied contents to your clipboard!